About IJCPCR

FORMULATION, OPTIMIZATION AND EVALUATION OF NANO PARTICULATE SYSTEM OF RIVASTIGMINE FOR TREATMENT OF ALZHEIMER
Article Information
Language English
Corres.Author Sajal Kumar Chowdhury
Email chowdhurysajal2016@gmail.com
Accepted Date
File size
No of Downloads 262
Published by IJCPCR
Full Text
There are a number of restrictions to present therapies, and the intranasal methodology looks to be a possible way for medication delivery to the brain. "Neurotransmitter or enzyme modulation is the basis of the right now permitted medications for treating cognitive disorders associated with AD. Inhibitors of acetyl cholinesterase (AChE) have been associated with gastrointestinal side effects like nausea and vomiting, which frequently lead to the discontinuation of therapy. The formulation F-2 SLNs were studied for stability study as per ICH guidelines. The formulation was stable at room temperature with minor change in particle size in three months. The initial particle size at day 0 was 138.22+0.01 nm and the size after 3 months were 139±0.4 nm. This minor increase in particle size may be due to the weak Vander Waals force that holds the particles together which lead to the formation soft agglomerates. Thus, SLNs were stable at room temperature for 3 monthsddd